Tolerance of normal human brain to boron neutron capture therapy.
Data from the Harvard-MIT and the BNL Phase I and Phase I/II clinical trials, conducted between 1994 and 1999, have been analyzed and combined, providing the most complete data set yet available on the tolerance of the normal human brain to BPA-mediated boron neutron capture therapy. Both peak (1cm(3)) dose and average whole-brain dose show a steep dose-response relationship using somnolence syndrome as the clinical endpoint. Probit analysis indicates that the doses associated with a 50% incidence for somnolence (ED(50)+/-SE) were 6.2+/-1.0 Gy(w) for average whole-brain dose and 14.1+/-1.8 Gy(w) for peak brain dose.
Coderre
J A
JA
Nuclear Engineering Department, Massachusetts Institute of Technology, 150 Albany Street, Cambridge, MA 02139, USA. coderre@mit.edu
Hopewell
J W
JW
Turcotte
J C
JC
Riley
K J
KJ
Binns
P J
PJ
Kiger
W S
WS
Harling
O K
OK
D001896:Boron Compounds / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy / Q000009:adverse effects*; D001921:Brain / Q000528:radiation effects*; D001932:Brain Neoplasms / Q000532:radiotherapy; D006970:Disorders of Excessive Somnolence / Q000209:etiology; D005909:Glioblastoma / Q000532:radiotherapy; D006801:Humans; D008545:Melanoma / Q000532:radiotherapy; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011836:Radiation Tolerance
C436045:4-dihydroxyborylphenylalanine; D001896:Boron Compounds; D010649:Phenylalanine